Author | Giuliana Grossi

Findings suggested that actigraphy may provide additional information to self-reported sleep measures in patients with rheumatoid arthritis.

Consultation aids can elevate communication around rheumatic and musculoskeletal disease, therefore promoting shared decision making between patients and clinicians.

Two phase 3 studies, BE OPTIMAL and BE COMPLETE, evaluated bimekizumab in adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders.

Secukinumab is the only biologic treatment in the US that’s approved by the FDA for children and adolescents with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).

The risk of adverse outcomes increased the most in pregnancies with antirheumatic treatment, especially those treated with biologic disease modifying antirheumatic drugs (bDMARDs), when compared with controls.

Upadacitinib achieved positive results from both Phase 3 SELECT-AXIS clinical trials, which focused on patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.